Merck's Molnupiravir has just narrowly been voted - 13/10 - in favour of energency use, even after 4 days previously, it reduced its efficacy from 50% to 30% in its primary end point. It seems that they Trumped up their results so as to gain access to the fast track panel, then lowered them before the meeting once the the agenda had been set.
The main issue with the panel's hesitation was what we are discussing, that is, the unknowns about how mutagenic drugs can also benefit the virus rather than diminish it as intended. This may have been the case with Omicron. There are also issues of long term effects, especially with pregnantcy and children.
I think it will be a certainty that if Molnupiravir is linked causally to the Omicron's development, then its shelf life will come to an immediate expiry date.
What then if BIT225 was accepted into CTAP - coronavirus accelerated treatment program or similiar ?
Anyway, regardless of what Merck achieves or not, Biotron's results stand alone and will speak for themselves at the appropriate - forthcoming - time. No amount of other successful drugs will interfere with our process. This is because BIT225 is only one decision away from entry into the big league, which is only one step behind Merck and Pfizer's therapeutics, and that step is only bureaucratic.
Technically, it may be one step ahead considering its high safety profile and excellent in vivo trial results.
If BIT225 enters human trials and interim analaysis results show favourable, it wouldn't be the first trial to finish early..... but now my echo location is getting ahead of my wings...
BIT Price at posting:
8.5¢ Sentiment: Buy Disclosure: Held
